The FDA and European Medicines Agency have approved a biologics license application (BLA) and marketing authorization application for tebentafusp (IMCgp100) in the treatment of patients with HLA-A*02:01–positive metastatic uveal melanoma, according to a press release from agent’s developer, Immunocore Holdings.1
The submissions are based on findings from the phase 3 IMCgp100-202 trial (NCT03070392), which evaluated tebentafusp in a population of patients with previously untreated metastatic uveal melanoma.2 Data from the study, which were presented at the 2021 American Association for Cancer Research Annual Meeting, indicated that after a median follow up of 14.1 months, patients treated with the experimental agent experienced a median overall survival (OS) of 21.7 months (95% CI, 18.6-23.6) compared with investigator’s choice of pembrolizumab (Keytruda), ipilimumab (Yervoy), or dacarbazine at 16.0 months (95% CI, 9.7-19.4; stratified HR, 0.51; 95% CI, 0.37-0.71; P <.0001). Moreover, the 1-year OS rate was 73.2% in the tebentafusp arm vs 58.5% in the control arm.
The priority review designation for the novel T-cell receptor bispecific immunotherapy agent could shorten the review period from a standard 10 months to 6 months from the filing acceptance. As such, the anticipated Prescription Drug User Fee Act date is February 23, 2022.
The BLA is currently being reviewed under the Real-Time Oncology pilot program, which is designed to expedite the delivery of tolerable and efficacious treatments for patients with cancer. Tebentafusp is also being assessed by the FDA’s Orbis initiative, which allows for concurrent review by health authorities in partner countries. Previously, the FDA had granted tebentafusp a breakthrough therapy designation as a treatment for adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use,
BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.
Stock image by @vitanovski from Depositphotos